BMAL1 and Anxiety: Bmal1 ablation alone did neither affect depression-like behavior assessed during the baseline tail suspension test (TST) or nosepoke sucrose preference test (SPT) (Fig. 3g, h) nor influenced general locomotor and anxiety-related behavior measured in the IntelliCage and open-field test (OFT) (Supplementary Fig. 3c, d).